Boston Private Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boston Private Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$41K	Sell	325 -500	-61%	-$53K	﹤0.01%	603
2014 Q4	$75K	Buy	825 +500	+154%	+$41.6K	﹤0.01%	508
2014 Q3	$23K	Hold	325	–	–	﹤0.01%	743
2014 Q2	$20K	Buy	+325	New	+$19.6K	﹤0.01%	738

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Boston Private Bank & Trust's BMRN Position: Q1 2015 in Review

Boston Private Bank & Trust reduced its BioMarin Pharmaceuticals (BMRN) stake by 61% in Q1 2015, selling an estimated $53K and leaving 325 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #603.

Boston Private Bank & Trust first reported a position in BMRN in Q2 2014 and has held it in 4 quarters since. The position peaked at $75K in Q4 2014. 378 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

Boston Private Bank & Trust held 325 shares of BioMarin Pharmaceuticals worth $41K as of Q1 2015.
Boston Private Bank & Trust sold 500 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $53K.
BioMarin Pharmaceuticals made up ﹤0.01% of Boston Private Bank & Trust's portfolio in Q1 2015, its #603 holding.
Boston Private Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 4 quarters since.
Boston Private Bank & Trust's BioMarin Pharmaceuticals position peaked at $75K in Q4 2014.
378 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Boston Private Bank & Trust's 13F filing for Q1 2015, filed 9 Apr 2015.